New data and analyses supporting the use of donidalorsen in HAE to be presented at 2025 AAAAI Annual Meeting

The latest data on a new medicine for HAE, donidalorsen (brand name Dawnzera), is to be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Scientific Meeting taking place in Philadelphia, Pennsylvania from 26 February – 2 March 2026.

Kenneth Newman MD, Senior Vice President, Clinical Development at Ionis, said: “These data add to a growing body of evidence outlining the clinical value of Dawnzera for people living with HAE, highlighting its potential to deliver meaningful improvement in HAE attack rate and quality of life, including for those switching from another long-term prophylactic therapy. We know that patients continue to seek out a treatment that meaningfully reduces attack frequency and severity while also addressing the administration and lifestyle burden of long-term therapy. The breadth of data being presented at AAAAI underscores the potential for Dawnzera to meet these needs.”

A total of eight posters will be presented at the conference:

  • Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks: Findings from the OASISplus Study
  • Real-world Adherence and Persistence with Long-term Prophylaxis among Patients with Hereditary Angioedema
  • Safety and Efficacy of Donidalorsen in Adolescent Patients With Hereditary Angioedema: 1-Year Results From OASISplus
  • Patient-Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema: Insights from OASIS-HAE
  • The Relationship Between Objective Disease Control at Baseline and Change in Subjective Disease Control and Quality of Life in Patients with Hereditary Angioedema Receiving Donidalorsen
  • Predictors of Disease Control, Attack Rate, and Quality of Life in HAE: An Exploratory Analysis
  • Unmet Treatment Need in a Real-World US Population of Patients with Hereditary Angioedema Treated for Over a Year with Long-Term Prophylaxis
  • Rethinking Severity Assessment in Hereditary Angioedema: Insights from Patient Experiences

In addition, on 25 February 2026, Ionis provided a financial and business update. According to the reporting, in the final quarter of 2025, Dawnzera had encouraging early launch momenturm; had been approved in the European Union (EU); and saw positive results from an open label extension of the Phase-3 study, OASISplus.

(Source: Ionis)